BioAdaptives Q2 10-Q: Going Concern, Cash Crunch, and Massive Dilution from Debt Conversions
BDPT has more than doubled off its 52-week low of $0.001 on light trading volume (0.3× avg).
Summary
BioAdaptives' Q2 2026 filing reveals a critical cash position, ongoing going concern doubts, and significant dilution from debt conversions, with more share issuance planned.
Key Events · Earnings and Guidance · BDPT
-
Going Concern and Cash Crunch
Cash fell to $29,221 as of June 30, 2026, from $158,445 at year-end, while current liabilities stand at $1.84 million. The company reiterated substantial doubt about its ability to continue as a going concern.
-
Debt Default Continues
The company remains in default on 12% Debentures issued in 2018 that were originally due in 2020, with no resolution reported.
-
Massive Dilution from Debt Conversion
Note holders converted $14,950 of principal and $26,276 of accrued interest into 19,586,449 common shares during the six months ended June 30, 2026.
-
Planned Future Share Issuance
To mitigate going concern risk, the company plans to issue additional shares of common stock for cash and services during the next 12 months, indicating further dilution.
Analysis · BDPT · Life Sciences
With only $29,221 in cash against $1.84 million in current liabilities and an accumulated deficit of $10.68 million, BioAdaptives reiterated substantial doubt about its ability to continue as a going concern. The company also disclosed it remains in default on 2018 debentures. During the quarter, note holders converted $41,226 of debt into 19.6 million shares, and the company plans to issue more shares for cash and services over the next 12 months, signaling further dilution ahead. The reported net income of $150,090 for the quarter is entirely due to a non-cash gain from derivative liability remeasurement, not operational improvement.
At the time of this filing, BDPT was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $28.2K. The 52-week trading range was $0.00 to $0.12. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.